DIGNITY HEALTH

DIGNITY HEALTH has been granted 156 US utility patents between 2015 and 2025, placing DIGNITY HEALTH at rank #2,501 across all assignees tracked by PlainPatent. This portfolio spans 53 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.0 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, DIGNITY HEALTH is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 57.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 110 grants, compared with 46 in the 2015–2019 window — a +139% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. DIGNITY HEALTH's 15.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 53 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark DIGNITY HEALTH against peers pursuing similar technology classes.